People investigating the relationship between GLP-1 and endometriosis should note that endometriosis patients are approximately 80% more likely to develop IBD, making this concern especially pertinent
When comparing natural GLP-1 supplements, clinical validation sets Supergut apart
On May 2, 2026, The Lancet published a randomized, double-blind, placebo-controlled trial (Klausen et al., Copenhagen University Hospital) testing once-weekly semaglutide 2.4 mg in 108 treatment-seeking adults with moderate to severe alcohol use disorder and comorbid obesity
If you have the disease of obesity, you are at excess risk for more than 200 conditions, so a small amount of risk of side effects on the balance is so much lower than continuing with all this excess risk from the disease
Who Benefits Most from GLP-1
It is important to note that no universal definition of clinically significant weight regain exists